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Abstract Overexpression of cyclin D1 has been implicated in a
variety of tumors, such as breast cancers, gastrointestinal
cancers and lymphomas. Both gene amplification and protein
degradation mediated by ubiquitin (Ub)-dependent proteolysis
regulate the abundance of cyclin D1. Here we report that ROC1
interacted with all three D type cyclins in vivo but did not bind to
other cyclins tested. The ROC1^CUL1 and ROC1^CUL3, but
not ROC1^CUL2, ^CUL3 and ^CUL4, immunocomplexes
promoted polyubiquitination of bacterially purified cyclin D1 in
vitro. RING finger mutations of ROC1 eliminated the Ub ligase
activity toward cyclin D1. In all cases the ubiquitination of cyclin
D1 was accompanied by autoubiquitination of the cullins.
The results suggest the involvement of ROC1^cullin ligases in
cyclin D1 ubiquitination and a potential mechanism whereby the
cullin subunit is ubiquitinated itself while ubiquitinating a
substrate. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
Key words: Cyclin D1; ROC1; Cullin; Ubiquitin ligase;
SKP1^CUL1(CDC53)^F-box protein complex
1. Introduction
In mammalian cells mitogenic signals sequentially activate
the transcription of D-type cyclins during G1 progression,
resulting in the activation of cyclin-dependent kinase
(CDK)4/6. Phosphorylation of Rb proteins by CDK4/6 re-
leases the repression of E2F target genes and permits the
G1/S transition [1]. While the levels of cyclins oscillate, the
steady state levels of CDK proteins are relatively constant
throughout the cell cycle as well as in cell cycle withdrawn
terminally di¡erentiated cells. Withdrawal of mitogens arrests
cells in G1 primarily through cessation of D-type cyclin syn-
thesis. Conversely, overexpression of D-type cyclins can over-
come a mitogen-deprivation-imposed G1 arrest allowing ab-
normal entry into the cell cycle [2]. Supporting this notion,
ectopic overexpression of cyclin D1 promotes cell cycle entry
and causes cell transformation in vivo [3]. Two major mech-
anisms, the gene ampli¢cation of cyclin D1 and the increased
protein stability of cyclin D1 have been linked with oncogen-
esis of di¡erent types of human cancers [4,5]. The protein
stability of cyclin D1 is normally regulated by ubiquitin
(Ub)-dependent proteolysis [6].
Ub-mediated proteolysis begins with activation of Ub in an
ATP-dependent manner by a Ub-activating enzyme (E1) [7].
The charged Ub forms a high-energy thiolester bond with the
E1 and is passed to a cysteine residue within an Ub-conjugat-
ing enzyme (E2). The E2-linked Ub is then transferred to a
lysine residue in the substrate to form a terminal isopeptide
bond, as targeted by a Ub ligase (E3). The proteins covalently
conjugated with polyubiquitin chains are rapidly degraded by
the 26S proteasome. Because the E3 provides substrate spe-
ci¢city, elucidating the mechanism and the regulation of E3
ligase activity have become critical issues central to our under-
standing of regulated proteolysis.
Previously, we and others identi¢ed a highly conserved
small RING ¢nger protein, ROC1 (also called Rbx1 and
Hrt1), as an essential subunit of the SKP1^CUL1(CDC53)^
F-box protein (SCF) Ub ligase [8^11]. The SCF and the ana-
phase-promoting complex (APC) are the two major Ub ligase
complexes that regulate Ub-mediated proteolysis during G1/S
and anaphase [12], and contain the small RING ¢nger pro-
teins ROC1 and APC11, respectively [8]. ROC1 commonly
interacts with all cullins while APC11 speci¢cally interacts
with cullin-related APC2 [8]. Point mutations in the RING
¢nger domain of ROC1 completely disrupted the Ub ligase
activity, suggesting the domain’s essential role in the activity
[8]. ROC1^SCF catalyzes ubiquitination of phosphorylated
IUBK from humans and G1 cyclin Cln2 and CDK inhibitor
Sic1 from yeast [8^11]. Several studies support ROC1^SCF’s
ubiquitination of cyclin D1 in humans. The interaction be-
tween CUL1 and cyclin D1 in vivo was previously reported
[13,14]. Treatment of cells with speci¢c antisense oligonucleo-
tides against either CUL1, SKP1 or SKP2 caused the accu-
mulation of cyclin D1 protein [13]. However, the in vitro
ubiquitination of cyclin D1 using these Ub ligases has not
been shown. In this report we provide the evidence showing
that ROC1^CUL1 and ROC1^CUL3 can catalyze cyclin D1
ubiquitination in vitro. We also demonstrate that the ubiqui-
tination of cyclin D1 is accompanied by ubiquitination of the
cullin subunit. The results suggest a potential mechanism
whereby cullins are autoubiquitinated while targeting a sub-
strate.
2. Materials and methods
2.1. Plasmids and antibodies
Constructs for human ROC1 and all cullins were previously de-
scribed [8] except that three repeats of the myc epitope were linked
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for the myc-tagged cullins. Expression plasmids for cyclins were gifts
from Dr. Yue Xiong (The University of North Carolina at Chapel
Hill, NC, USA). ROC1 point mutations were introduced by site-di-
rected mutagenesis (Stratagene) and veri¢ed by DNA sequencing.
Mouse monoclonal anti-hemagglutinin (anti-HA; 12CA5, Boehr-
inger-Mannheim), anti-myc (9E10, NeoMarkers) and anti-cyclin A
(E72, NeoMarkers) antibodies were purchased commercially. Rabbit
polyclonal antibodies recognizing a glutathione-S-transferase fusion
full-length human cyclin B1 and polypeptides corresponding to the
C-termini of human cyclins D1, D2, D3 and E1, were gifts from
Dr. Yue Xiong. Rabbit anti-CUL1 antibody was previously described
[8].
2.2. Cell culture, transfection, immunoprecipitation and immunoblotting
293T or Saos2 cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium (Sigma) supplemented with 10% fetal bovine serum (Life
Technologies) and 1% antibiotic^antimycotic agent (Life Technolo-
gies) in a 37‡C incubator with 5% CO2. Plasmid DNA was transfected
using the standard calcium phosphate precipitation method (for 293T
cells) or the LipofectAMINE (Gibco BRL) reagent according to the
manufacturer’s instructions (for Saos2 cells). For each transfection,
the total plasmid DNA was adjusted to 5 or 15 Wg per 60 or 100 mm
dish, respectively, by adding the parental pcDNA3 vector if necessary.
For coupled 35S-labeling and immunoprecipitation, Saos2 cells cul-
tured in 60 mm dishes were metabolically labeled with [35S]methionine
(0.15 mCi) 24 h after transfection, and then lysed and immunopreci-
pitated using 1 Wg of anti-HA antibody or 1 Wl of anti-cyclin sera as
described elsewhere [15,16]. For the ROC1^cullin immunoprecipita-
tion used in the in vitro Ub ligation assay, 293T cells were harvested
36 h after transfection and lysed by incubating at 4‡C for 1 h with 0.6
ml per 100 mm dish of bu¡er A containing 15 mM Tris^HCl pH 7.5,
0.5 M NaCl, 0.35% NP-40, 1 mM phenylmethylsulfonyl £uoride, 2
Wg/ml aprotinin, 2 Wg/ml leupeptin, 10 Wg/ml trypsin inhibitor, and
150 Wg/ml benzamidine. Lysed cells were then clari¢ed by centrifuga-
tion at 100 000Ug at 4‡C for 1 h. The supernatants (0.3 ml) were
mixed with 3 Wg of anti-myc or anti-HA antibody, and precipitated
with protein A-agarose beads (Pierce; 7.5 Wl). The proteins bound to
the beads were used either for the Ub ligation assay or direct immu-
noblotting. The concentrations of the primary antibody used for the
immunoblotting were anti-HA (1 Wg/ml), anti-myc (1 Wg/ml), anti-
cyclin D1 serum (1:3000 dilution) and anti-CUL1 (1 Wg/ml).
2.3. Enzymes and protein puri¢cation
Puri¢ed human cyclin D1 was a gift from Dr. Hideaki Higashi
(Institute for Genetic Medicine, Hokkaido University). Puri¢ed rabbit
E1 (A⁄niti Research Products, Exeter, UK) and bovine Ub (Sigma)
were purchased commercially. His-tagged UbcH5c and His-tagged
mouse CDC34 were previously described [8,15].
2.4. Ub ligation assay
The ROC1^cullin immunocomplexes immobilized on protein A-
agarose beads were washed three times with bu¡er A and twice
with bu¡er containing 25 mM Tris^HCl pH 7.5, 50 mM NaCl,
0.01% NP-40, 10% glycerol and 1 mM EDTA, and added to an Ub
ligation reaction mixture (¢nal volume 30 Wl) containing 50 mM Tris^
HCl pH 7.4, 5 mM MgCl2, 2 mM NaF, 10 nM okadaic acid, 2 mM
ATP, 0.6 mM dithiothreitol (DTT), 40 ng E1, 300 ng E2, 50 ng of
puri¢ed cyclin D1 and 12 Wg of unlabeled bovine Ub. After incuba-
tion for 30 min at 37‡C with shaking, the reactions were terminated
by boiling in Laemmli sodium dodecyl sulfate (SDS)-loading bu¡er
with 0.1 M DTT and half of the sample was resolved by SDS^poly-
acrylamide gel electrophoresis (SDS^PAGE) followed by immuno-
blotting with either anti-cyclin D1, anti-CUL1 or anti-myc antibody.
3. Results
3.1. In vivo interaction of ROC1 with all D-type cyclins
In yeast the ubiquitination of G1 cyclin Cln2 is mediated by
ROC1^SCF. To determine whether ROC1^SCF Ub ligases
can be implicated in the ubiquitination of any human cyclins,
we ¢rst tested the in vivo interaction between ROC1 and
cyclins by examining immunocomplexes of ectopically ex-
pressed proteins. Saos-2 cells were transfected with plasmids
directing the expression of HA-tagged human ROC1 (HA-
ROC1) together with either cyclin A, B1, D1, D2, D3 or
E1. Transfected cells were metabolically labeled with
[35S]methionine, and cell lysates were immunoprecipitated
with either K-HA, or antibody to each cyclin. All three D-
type cyclins were co-precipitated with ROC1 by the K-HA
antibody (Fig. 1, lanes 6, 8 and 10), but none of the other
cyclins (lanes 2, 4 and 12). Replacement of pcDNA3-HA-
ROC1 by the parental empty pcDNA3 vector eliminated the
possibility of non-speci¢c interaction between the anti-HA
antibody and the D-type cyclins (lanes 14, 16 and 18). The
results indicate that ROC1 can interact with D-type cyclins
either directly, or indirectly through the complex associated
with ROC1.
3.2. E1 and E2/UbcH5c-dependent ubiquitination
of cyclin D1 by ROC1^CUL1 is accompanied by
CUL1 autoubiquitination
The interaction between the ROC1 immunocomplex and
the D-type cyclins prompted us to determine whether the cy-
clins are ubiquitinated by the ROC1 complex. We have pre-
viously shown that ROC1^CUL1 is capable of collaborating
with two E2s, CDC34 and UbcH5c, to promote polyubiquiti-
nation [8]. Therefore, we ¢rst determined which E2 could
collaborate with ROC1^CUL1 to promote cyclin D1 ubiqui-
tination. An in vitro ubiquitination assay was performed using
bacterially puri¢ed cyclin D1 protein, followed by detection
with anti-cyclin D1 immunoblotting. Several slow migrating
cyclin D1 species were detected when cyclin D1 was incubated
with E1, E2/UbcH5c and HA-ROC1^CUL1 immunocom-
plexes (Fig. 2A, lane 2), which were not detected when
UbcH5c was replaced with CDC34 (lane 1). Such slowly mi-
grating products were promoted in an E1 (Fig. 2B, lane 1) and
an E2/UbcH5c (lane 2)-dependent manner, indicating that
they are ubiquitinated products. Incubation with HA immu-
Fig. 1. Co-immunoprecipitation of D-type cyclins with ROC1.
Saos2 cells cotransfected with the indicated cyclin plasmids and
HA-ROC1 (left panel) or parental pcDNA3 plasmids (right panel)
were metabolically labeled with [35S]methionine. The 35S-labeled
proteins were immunoprecipitated with indicated antibodies and re-
solved by SDS^PAGE followed by autoradiography. Arrows indi-
cate D-type cyclins coprecipitated with HA-ROC1 by the anti-HA
antibody.
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nocomplexes from cells transfected with myc-CUL1 alone did
not result in cyclin D1 ubiquitination (lane 4), excluding the
possibility of a non-speci¢c precipitation of the Ub ligase
activity by the anti-HA antibody. The cyclin D1 polyubiquiti-
nation catalyzed by ROC1^CUL1 was time^course-dependent
(Fig. 2C). Interestingly, when cyclin D1 was ubiquitinated,
CUL1 (either myc-CUL1 or untagged CUL1) was simultane-
ously ubiquitinated (Fig. 2B, top panel, lane 3 and Fig. 2C,
top panel, lanes 3 and 4). Ubiquitination of recombinant,
unphosphorylated cyclin D1 suggests that the in vitro cyclin
D1 ubiquitination by ROC1^CUL1 observed may not require
substrate phosphorylation.
3.3. The RING ¢nger of ROC1 is essential for the
polyubiquitination of both cyclin D1 and CUL1
To seek direct evidence that the RING ¢nger of ROC1 was
essential for the observed Ub ligase activity directed toward
either cyclin D1 or CUL1, we tested several point mutations
of ROC1 for ligase activity. While ROC1T9A=P10A, a mutation
outside of the RING ¢nger, did not a¡ect the ubiquitination
of cyclin D1 (Fig. 3, upper middle panel, lane 5), RING ¢nger
mutations of ROC1, ROC1C53A=C56A and ROC1C75A=H77A, sig-
ni¢cantly reduced the ubiquitination (lanes 3 and 4) without
disrupting the association of ROC1 with CUL1 (lower middle
panel). The autoubiquitination of myc-CUL1 was also abol-
ished by the RING ¢nger mutations (top panel, lanes 2 and
5). These results indicate that the RING ¢nger of ROC1 is
essential for the polyubiquitination of both cyclin D1 and
CUL1.
3.4. Cyclin D1 can be ubiquitinated by ROC1^CUL1 and
ROC1^CUL3
ROC1 and ROC2 commonly interact with all the cullins
and constitute a number of active Ub ligases. We next exam-
ined whether other ROC1^CUL complexes could catalyze the
ubiquitination of cyclin D1. Puri¢ed recombinant cyclin D1
was incubated with myc immunocomplexes derived from cells
transfected with HA-ROC and individual myc-tagged cullins.
Two of ¢ve immunocomplexes tested, ROC1^CUL1 (Fig. 4,
lower panel, lane 2) and ROC1^CUL3 (lane 4), were capable
of catalyzing cyclin D1 ubiquitination in the presence of E1
and E2/UbcH5c. The cyclin D1 ubiquitination was not de-
tected in myc-CUL2, myc-CUL4A or myc-CUL5 immuno-
complexes (lanes 3, 5, and 6). The ubiquitination of cyclin
D1 by ROC1^CUL1 and ROC1^CUL3 was accompanied
by autoubiquitination of CUL1 and CUL3, respectively
(upper panel, lanes 2 and 4).
4. Discussion
The in vivo interaction between ROC1 and cyclin D1, and
the in vitro ubiquitination of cyclin D1 by ROC1^CUL1 and
ROC1^CUL3 presented in this report indicate the potential of
these complexes as intrinsic Ub ligases for cyclin D1. More
Fig. 2. In vitro ubiquitination of cyclin D1 by the ROC1^CUL1 im-
munocomplex. A: Puri¢ed cyclin D1 was incubated with Ub, E1,
E2 (Cdc34 or UbcH5c as indicated) and anti-HA immunocomplexes
derived from 293T cells transfected with HA-ROC1 and CUL1. The
reactants were resolved by SDS^PAGE followed by anti-cyclin D1
immunoblotting. B: In vitro cyclin D1 ubiquitination was performed
as in (A) except that myc-CUL1 was used instead of CUL1, with
the combination of E1, E2/UbcH5c and HA-ROC1 as indicated.
The ubiquitinated products of myc-CUL1 (top panel) and cyclin D1
(bottom panel) were detected with anti-myc and anti-cyclin D1 im-
munoblotting, respectively. The myc-CUL1 before the reaction was
veri¢ed with anti-myc immunoblotting (middle panel). C: In vitro
cyclin D1 ubiquitination was performed as in (A) with E2/UbcH5c
for various lengths of time as indicated. The ubiquitinated products
of CUL1 (upper panel) and cyclin D1 (lower panel) were detected
with anti-CUL1 and anti-cyclin D1 immunoblotting, respectively.
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direct in vivo evidence is needed to ¢rmly establish the func-
tion of ROC^cullin Ub ligases in targeting the ubiquitination
and degradation of D-type cyclins. The in vitro assay of cyclin
D1 ubiquitination reported here should facilitate future inves-
tigation into this issue. Two models present themselves to
explain how the ROC1^CUL1 complex targets cyclin D1 for
ubiquitination. One involves the ubiquitination of cyclin D1
through the ROC1^SCF complex, and the other is through a
mechanism independent of SKP1 and F-box proteins. A com-
mon feature of the known F-box proteins, such as Cdc4 and
L-TRCP, is the targeting of a phosphorylated substrate, such
as Sic1 and IUBK, respectively [17,18]. Phosphorylation of
cyclin D1 on threonine 286 by GSK-3L is required for the
ubiquitination of cyclin D1 bound to CDK4 [6,19]. However,
ubiquitination of free cyclin D1 can also occur independent of
phosphorylation on threonine 286 [20]. The Ub ligase catalyz-
ing the unphosphorylated substrate may be di¡erent from the
one catalyzing phosphorylated, CDK4-bound cyclin D1. The
bacterially puri¢ed cyclin D1 used in the present study was
not phosphorylated, suggesting the ubiquitination of cyclin
D1 was mediated by a non-SCF mechanism that does not
require endogenous SKP1 and F-box proteins to be co-pre-
cipitated with the ROC1^CUL1 immunocomplex. Supporting
this hypothesis, ROC1^CUL3, which does not interact with
SKP1 [21], also showed Ub ligase activity with cyclin D1 as a
substrate. Two di¡erent pathways exist for cyclin E1 ubiquiti-
nation as well. Cyclin E1 protein accumulated in mice de¢-
cient for SKP2 [22], but was also elevated in mice de¢cient for
CUL3 [23]. CUL3 interacts with free, unphosphorylated cy-
clin E1 [23]. Such complementary mechanisms may generally
exist for di¡erent substrates. Whether ROC1^CUL1 and
ROC1^CUL3 utilize alternative unknown subunits to target
the unphosphorylated substrate is not known. APC11 alone,
without the presence of the cullin homolog APC2, could acti-
vate E2 and ubiquitinate known APC substrates, such as se-
curin and cyclin B, in a destruction-box-independent manner,
suggesting that substrate speci¢city may already exist at the
level of RING ¢nger proteins [24,25].
Our data clearly showed the ubiquitination of CUL1 and
CUL3 in vitro. The ubiquitination of CUL1, as well as of its
substrate cyclin D1, was dependent on the RING ¢nger of
ROC1. Other subunits of ROC1^SCF, the F-box proteins
CDC4 and SKP2, have also been shown to be ubiquitinated,
and the ubiquitination of SKP2 was mediated by a CUL1-
based core Ub ligase complex [26,27]. The degradation of
ROC1 has been shown to be proteasome-dependent [15].
These data together with the present data suggest that most
of the subunits of the ROC1^SCF complex are autoubiquiti-
nated. Whether the autoubiquitination has some speci¢c role
in substrate ubiquitination or is just a result of non-speci¢c
Ub ligase activity of the core catalytic subunit is not known.
In the case of MDM2, a RING type Ub ligase for p53, mod-
Fig. 3. The e¡ect of Ub ligase activity on cyclin D1 and CUL1 in
the ROC1^CUL1 immunocomplexes for various mutants of ROC1.
293T cells were co-transfected with myc-CUL1 and either vector
DNA control, HA-tagged wild type, or HA-tagged ROC1 mutants
as indicated. In vitro cyclin D1 ubiquitination was performed as in
Fig. 1A with E2/UbcH5c and anti-HA immunocomplexes. The ubiq-
uitinated products of myc-CUL1 (top panel) and cyclin D1 (upper
middle panel) were detected with anti-myc and anti-cyclin D1 im-
munoblotting, respectively. ROC1^CUL1 complex formation was
examined by coupled IP^Western (lower middle and bottom panel).
Fig. 4. In vitro ubiquitination of cyclin D1 by ROC1^CUL1 and
ROC1^CUL3 Ub ligases 293T cells were co-transfected with HA-
ROC1 and either vector DNA control or myc-tagged cullins as indi-
cated. Individual ROC^cullin ligase complexes were precipitated
with anti-myc antibody and incubated with cyclin D1 in the pres-
ence of E1, UbcH5c and Ub. The reaction mixture was resolved by
SDS^PAGE followed by anti-myc (upper panel) or anti-cyclin D1
(lower panel) immunoblotting.
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i¢cation by SUMO-1 at K446 in the RING ¢nger increases its
Ub ligase activity toward p53 while protecting MDM2 from
autoubiquitination and degradation [28]. A similar mechanism
can be hypothesized for the ROC1^SCF Ub ligase complex.
Further study is needed to elucidate the signi¢cance of the
autoubiquitination of the ROC1^SCF subunits, including
CUL1.
Cyclin D2 and cyclin D3 interact with ROC1 as well as
cyclin D1, indicating that they may also be ubiquitinated by
ROC1 containing Ub ligases. In breast cancer cell lines both
cyclin D1 and cyclin D3 interact with CUL1, and the expres-
sion level of the two proteins is coordinately elevated, suggest-
ing that cyclin D1 and cyclin D3 share a common mechanism
of degradation [14]. Since the expression level of cyclin D is
related to the potential for malignancy and the prognosis of a
variety of cancers, revealing the mechanisms governing the
Ub-dependent proteolysis of D-type cyclins is a critical issue
in designing therapeutics for cyclin D-overexpressing cancers.
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